(Q33708288)

28 July 2017

title

Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications (English)

1 reference

28 July 2017

A. Jon Stoessl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20887875

24 July 2024

Renju Kuriakose

1 reference

28 July 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20887875

24 July 2024

publication date

1 January 2010

1 reference

Progress in Brain Research

28 July 2017

published in

1 reference

28 July 2017

volume

184

1 reference

28 July 2017

page(s)

177-192

1 reference

Slowing Parkinson's disease progression: recent dopamine agonist trials

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Initial agonist treatment of Parkinson disease: a critique

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

The functional anatomy of basal ganglia disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Network modulation in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Parkinson's disease: in vivo assessment of disease progression using positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Prevalence of pathological gambling in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Relationship of striatal dopamine synthesis capacity to age and cognition

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Criteria for diagnosing Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Advances in understanding L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Dopamine agonist monotherapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

The discovery of epidepride and its analogs as high-affinity radioligands for imaging extrastriatal dopamine D(2) receptors in human brain

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Neuroimaging and therapeutics in movement disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Quantification of Parkinson's disease-related network expression with ECD SPECT.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Compulsive drug use linked to sensitized ventral striatal dopamine transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Impulsive and compulsive behaviors in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Levodopa and the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Ageing and Parkinson's disease: substantia nigra regional selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Young-onset Parkinson's disease: a clinical review

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Risk factors for levodopa-induced dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Problematic gambling on dopamine agonists: Not such a rarity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Biochemical aspects of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Changes in network activity with the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Levodopa-dyskinesia incidence by age of Parkinson's disease onset

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C]raclopride study in healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Pharmacological and PET studies in patient's with Parkinson's disease and a short duration-motor response: implications in the pathophysiology of motor complications.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Dyskinesia after fetal cell transplantation for parkinsonism: a PET study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

[123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Punding prevalence in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Functional imaging in Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Levodopa-induced dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Factors affecting the clinical outcome after neural transplantation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

[123I]epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: implications for the use of cerebellum as a reference region

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Correlation of dopamine transporter imaging with parkinsonian motor handicap: How close is it?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Young onset Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

The role of radiotracer imaging in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Mitochondria in the etiology and pathogenesis of parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

What contributes to quality of life in patients with Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Reward signaling by dopamine neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

A mathematical model of pathogenesis in idiopathic parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

A reversible tracer analysis approach to the study of effective dopamine turnover

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Agonizing over dopaminergic replacement therapy--lessons from animal models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Apoptosis in Parkinson's disease: signals for neuronal degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

PET demonstrates reduced dopamine transporter expression in PD with dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

In vivo studies on striatal dopamine D 1 and D 2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

[3H]methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Decreased dopamine transporters with age in health human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Prevalence of repetitive and reward-seeking behaviors in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Association of dopamine agonist use with impulse control disorders in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

Late Progression of Post-Encephalitic Parkinson's Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6123%2810%2984009-9

1 reference

7 January 2021

A new PET ligand for the dopamine transporter: studies in the human brain

series ordinal

123

1 reference

10.1016/S0079-6123(10)84009-9

DOI

https://api.crossref.org/works/10.1016/S0079-6123(10)84009-9

10.1016/S0079-6123(10)84009-9

24 July 2024

Identifiers

DOI

1 reference

28 July 2017

1 reference